Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

PEG-MGF vs Hulk Stack

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

PEG-MGF and Hulk Stack share the igf-1 class and carry roughly equivalent evidence (Anecdotal / Anecdotal). On the catalogued data layer Hulk Stack has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Hulk Stack's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

PEG-MGF

Anecdotal

Hulk Stack

Anecdotal

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

PEG-MGF Hulk Stack
Class Pegylated IGF-1 splice variant; anabolic GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism PEG conjugation extends half-life of MGF for systemic action Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation.
Route SC / IM SC injection (typically 2-3 separate sites)
Half-life ~2-3 days CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs
Dosage (research) 200-400 mcg SC 1-2x weekly Reported research dosing: CJC-1295 100-200 mcg with Ipamorelin 100-200 mcg SC nightly; IGF-1 LR3 20-50 mcg SC. Reported cycles run 4-8 weeks followed by ~4 weeks off; longer cycles increase desensitisation and IGF-1R-mediated risks
Evidence tier Anecdotal Anecdotal
Research depth 1 indexed (PubMed 0 · CT 0 · EPMC 1) —
Availability Research Chemical Compounding Restricted
Reported risks Immunogenicity concerns with PEG; limited safety data Compounds the risk profile of three potent compounds: hypoglycaemia (IGF-1), receptor desensitisation (GHRH + GHRP), theoretical organomegaly with chronic IGF-1 LR3 use, IGF-1R-mediated growth signal on any pre-existing tumour, WADA-banned across competitive sport, injection-site reactions; not FDA-approved

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick PEG-MGF or Hulk Stack?

PEG-MGF and Hulk Stack share the igf-1 class and carry roughly equivalent evidence (Anecdotal / Anecdotal). On the catalogued data layer Hulk Stack has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Hulk Stack's evidence base is currently denser.

What is the difference between PEG-MGF and Hulk Stack?

PEG-MGF is classed as Pegylated IGF-1 splice variant; anabolic; Hulk Stack is classed as GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog. Reported mechanism: PEG-MGF, PEG conjugation extends half-life of MGF for systemic action; Hulk Stack, Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation. Reported half-life: PEG-MGF, ~2-3 days; Hulk Stack, CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs. Routes in published studies: PEG-MGF, SC / IM; Hulk Stack, SC injection (typically 2-3 separate sites).

Which has stronger evidence, PEG-MGF or Hulk Stack?

PEG-MGF and Hulk Stack sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. PEG-MGF is graded Anecdotal, with 1 cited source on its reference page and 1 indexed studies. Hulk Stack is graded Anecdotal, with 3 cited sources on its reference page.

Which is more accessible, PEG-MGF or Hulk Stack?

Neither PEG-MGF nor Hulk Stack is an FDA-approved drug. Catalog status: PEG-MGF, Research Chemical; Hulk Stack, Compounding Restricted. PEG-MGF's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.

Are PEG-MGF and Hulk Stack ever combined?

PEG-MGF and Hulk Stack appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…